Relay for Life keeps growing in Queens
Queens Chronicle Mon, 28 Feb 2011 06:00 AM PST
Last year’s Middle Village relay has an Olympics theme, top, while St. John’s University featured superheroes, bottom left, and the Alley Pond outing took time to honor cancer survivors. |
Study: Gene Testing of Fluid Specimens Helps Identify Cancer Origin
Business Wire via Yahoo! Finance Mon, 28 Feb 2011 06:00 AM PST
Pathwork Diagnostics, Inc., a privately held molecular diagnostics company focused on oncology, announced that results demonstrating the capability of its Tissue of Origin Test to be performed on a variety of FFPE fluid specimens will be presented this week at the 100th Annual Meeting of the United States and Canadian Academy of Pathology in San Antonio, TX. |
Doctors want teenagers banned from tanning salons
INO News Mon, 28 Feb 2011 05:58 AM PST
(AP:CHICAGO) The American Academy of Pediatrics wants teenagers banned from tanning salons to reduce their risk of skin cancer. More than 30 states regulate indoor tanning by minors, with some banning children younger than 14 or requiring parental permission. |
Chef's memoir tells of fight against tongue cancer
AP via Yahoo! News Mon, 28 Feb 2011 05:42 AM PST
"Life, on the Line: A Chef's Story of Chasing Greatness, Facing Death, and Redefining the Way We Eat" (Gotham Books, $27.50), by Grant Achatz and Nick Kokonas: |
Non Communicable Diseases: The World's Number One Killer For Women
Medical News Today Mon, 28 Feb 2011 05:34 AM PST
Non-communicable diseases (NCDs), including cancer, cardiovascular disease, chronic respiratory disease and diabetes, are the world's number one killer causing 60% of deaths globally. A staggering 35 million people die from NCDs, of which 18 million are women. These diseases represent a major threat to women's health, increasingly impacting on women in developing countries in their most ... |
Erlotinib Effective And With Fewer Side-Effects After First-Line Treatment
Medical News Today Mon, 28 Feb 2011 05:32 AM PST
The targeted cancer drug erlotinib has comparable efficacy to chemotherapy, and is better tolerated, in hard-to-treat cases where a patient's cancer has progressed quickly after treatment with first-line therapy, the results of a new phase III trial show. Dr Tudor Ciuleanu from the Institute of Oncology Ion Chiricuta, Cluj-Napoca, Romania, reported this finding from the international TITAN study ... |
Peregrine Announces Four Abstracts Accepted for Presentation at AACR Annual Meeting
Marketwire Mon, 28 Feb 2011 05:31 AM PST
TUSTIN, CA--(Marketwire - February 28, 2011) - Peregrine Pharmaceuticals, Inc. ( NASDAQ : PPHM ), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced that data from four studies investigating the company's lead phosphatidylserine (PS)-targeting clinical candidate bavituximab and other PS ... |
| |
|
No comments:
Post a Comment